Latest News About - Cytomegalovirus

 
Show/hide duplicate news articles.
Filter by countryfromabout
<<10<12345678910>>>10
 
Show/hide duplicate news articles.
<<10<12345678910>>>10

Tools

Load latest edition

Sunday, October 24, 2021

11:37:00 PM CEST

Subscribe
RSS | MAP

Language Selection

For any category/filter, users can choose:

  1. the language of the categorized news items (e.g. fr and de to display only those news items in French and German)
  2. the language of the user interface (e.g. it for Italian)

In Top Stories, the user can display the largest clusters of news items for one language only (e.g. en shows all clusters in English)

Country Selection

Users can choose:

  1. country mentioned in the news item (articles about a country)
  2. country in which the news item was published (articles from a country)

Languages Collapse menu...Expand menu...Open help...

Select your languages

ab
ar
az
be
bg
bs
ca
cs
da
de
el
en
eo
es
et
fa
fi
fo
fr
ga
gl
ha
he
hi
hr
hu
hy
id
is
it
ja
ka
km
ko
ku
ky
lb
lo
lt
lv
mk
ml
mn
ms
mt
my
ne
nl
no
ny
os
pap
pl
ps
pt
ro
ru
se
si
sk
sl
so
sq
sr
sv
sw
ta
th
tr
uk
ur
vi
zh
all
Show additional languagesHide additional languages

Interface:

Most reported countries (24h)

Theme countries

AlertLevel (24h)

Alert level graph

 Previous 14 days average

Alert level:
 high   medium   low

Quotes... Extracted quotes

Javier Cortes said: “This approval is an important milestone for appropriate patients with metastatic TNBC who are in need of new treatment options,” External link

eagletribune Friday, October 22, 2021 1:22:00 PM CEST

Vicki Goodman said: “At Merck, we are committed to improving outcomes for people with difficult-to-treat cancers, such as TNBC, around the world and are proud of this first European approval for KEYTRUDA in a breast cancer setting,” External link

eagletribune Friday, October 22, 2021 1:22:00 PM CEST

Javier Cortes said: “This approval is an important milestone for appropriate patients with metastatic TNBC who are in need of new treatment options,” External link

4-traders Friday, October 22, 2021 12:46:00 PM CEST

Vicki Goodman said: “At Merck, we are committed to improving outcomes for people with difficult-to-treat cancers, such as TNBC, around the world and are proud of this first European approval for KEYTRUDA in a breast cancer setting,” External link

4-traders Friday, October 22, 2021 12:46:00 PM CEST

Holger Zimmermann sagte: "Die Komplexität der Behandlung von infizierten, chronischen Wunden, die weder auf herkömmliche antiseptische Maßnahmen noch auf die systemische Gabe von Antibiotika ansprechen, schafft einen hohen und wachsenden medizinischen Bedarf. Darüber hinaus erfordert die zunehmende Resistenz gegen Antibiotika neue Ansätze und therapeutische Optionen" External link

onvista Friday, October 22, 2021 9:11:00 AM CEST

Markus Graf sagte: "Die heutige Ankündigung ist der nächste Schritt in unserer langfristigen Zusammenarbeit mit AiCuris. Chronische, nicht heilende Wunden sind eine starke Belastung und mit einer hohen Morbidität und Mortalität verbunden. Darüber hinaus stellen sie eine große Herausforderung für die Wundpflege dar, während sie gleichzeitig viele Ressourcen im Gesundheitswesen binden" External link

onvista Friday, October 22, 2021 9:11:00 AM CEST

Daily number of articles in this category

Trend data not available for this selection.